Ilyang Pharm (007570) - Total Liabilities

Latest as of June 2025: ₩205.41 Billion KRW ≈ $139.20 Million USD

Based on the latest financial reports, Ilyang Pharm (007570) has total liabilities worth ₩205.41 Billion KRW (≈ $139.20 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore 007570 operating cash flow to assess how effectively this company generates cash.

Ilyang Pharm - Total Liabilities Trend (2002–2024)

This chart illustrates how Ilyang Pharm's total liabilities have evolved over time, based on quarterly financial data. Check asset resilience ratio of Ilyang Pharm to evaluate the company's liquid asset resilience ratio.

Ilyang Pharm Competitors by Total Liabilities

The table below lists competitors of Ilyang Pharm ranked by their total liabilities.

Company	Country	Total Liabilities
Quipt Home Medical Corp NASDAQ:QIPT	USA	$167.66 Million
KEYEAST.Co.Ltd KQ:054780	Korea	₩19.16 Billion
Eastern Water Resources Development and Management Public Company Limited BK:EASTW	Thailand	฿16.37 Billion
Donga Geologic KO:028100	Korea	₩214.80 Billion
Horizon Gold Ltd AU:HRN	Australia	AU$13.24 Million
IRM ENERGY LTD NSE:IRMENERGY	India	Rs2.70 Billion
Satellos Bioscience Inc. TO:MSCL	Canada	CA$3.50 Million
Bisalloy Steel Group Ltd AU:BIS	Australia	AU$47.88 Million

Liability Composition Analysis (2002–2024)

This chart breaks down Ilyang Pharm's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Ilyang Pharm (007570) market capitalisation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	0.87	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.87	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.46	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Ilyang Pharm's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Ilyang Pharm (2002–2024)

The table below shows the annual total liabilities of Ilyang Pharm from 2002 to 2024.

Year	Total Liabilities	Change
2024-12-31	₩189.63 Billion ≈ $128.51 Million	+18.33%
2023-12-31	₩160.25 Billion ≈ $108.60 Million	-22.33%
2022-12-31	₩206.33 Billion ≈ $139.83 Million	-7.27%
2021-12-31	₩222.51 Billion ≈ $150.79 Million	+14.58%
2020-12-31	₩194.19 Billion ≈ $131.60 Million	-9.56%
2019-12-31	₩214.72 Billion ≈ $145.51 Million	-3.44%
2018-12-31	₩222.37 Billion ≈ $150.70 Million	-1.34%
2017-12-31	₩225.39 Billion ≈ $152.74 Million	+5.37%
2016-12-31	₩213.91 Billion ≈ $144.96 Million	-3.04%
2015-12-31	₩220.62 Billion ≈ $149.51 Million	-10.81%
2014-12-31	₩247.37 Billion ≈ $167.64 Million	+15.32%
2013-12-31	₩214.50 Billion ≈ $145.37 Million	+33.50%
2009-12-31	₩160.67 Billion ≈ $108.89 Million	+39.31%
2004-12-31	₩115.33 Billion ≈ $78.16 Million	+26.51%
2003-12-31	₩91.16 Billion ≈ $61.78 Million	-7.51%
2002-12-31	₩98.56 Billion ≈ $66.80 Million	--

About Ilyang Pharm

KO:007570 Korea Drug Manufacturers - Specialty & Generic

Market Cap

$158.52 Million

₩233.92 Billion KRW

Market Cap Rank

#17414 Global

#807 in Korea

Share Price

₩13050.00

Change (1 day)

+0.00%

52-Week Range

₩12290.00 - ₩15130.00

All Time High

₩95982.23